Neoleukin Therapeutics (Neoleukin Therapeutics) Long-Term Capital Lease Obligation : $9.14 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics Long-Term Capital Lease Obligation?

Neoleukin Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was $9.14 Mil.

Neoleukin Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 ($9.95 Mil) to Jun. 2023 ($9.55 Mil) and declined from Jun. 2023 ($9.55 Mil) to Sep. 2023 ($9.14 Mil).

Neoleukin Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2020 ($11.41 Mil) to Dec. 2021 ($11.76 Mil) but then declined from Dec. 2021 ($11.76 Mil) to Dec. 2022 ($10.56 Mil).

Neoleukin Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Neoleukin Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics Long-Term Capital Lease Obligation Chart

Neoleukin Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.01

0.59

11.41

11.76

10.56

Neoleukin Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															10.69	10.56	9.95	9.55	9.14

Neoleukin Therapeutics (NAS:NLTX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Neoleukin Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102

Website

https://www.neoleukin.com

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Executives

Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith	officer: Principal Accounting Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel	officer: Chief Medical Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle	director	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener	officer: General Counsel, SVP Legal	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar	director	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman	director, officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey	officer: Senior Vice President	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho	officer: Chief Financial Officer	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance	officer: General Counsel	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle	director	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080